Evidence map›Paper›PMID 40579560›Full record

SynthesisNeurosurgical review2025

Does duration of nimodipine therapy impact outcome in aneurysmal subarachnoid hemorrhage: systematic review and meta-analysis.

Spencer Oslin, Wilson Hoyt, Sherwin Tavakol, Hakeem Shakir, Andrew Bauer, Shyian Jen, Christopher Graffeo

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Spencer OslinDepartment of Neurosurgery, University of Oklahoma, 1000 N Lincoln Blvd, #4000, Oklahoma City, OKC, 73104, USA. SpencerOslin@gmail.com.
Wilson HoytDepartment of Neurosurgery, University of Oklahoma, 1000 N Lincoln Blvd, #4000, Oklahoma City, OKC, 73104, USA.
Sherwin TavakolDepartment of Neurosurgery, University of Oklahoma, 1000 N Lincoln Blvd, #4000, Oklahoma City, OKC, 73104, USA.
Hakeem ShakirDepartment of Neurosurgery, University of Oklahoma, 1000 N Lincoln Blvd, #4000, Oklahoma City, OKC, 73104, USA.
Andrew BauerDepartment of Neurosurgery, University of Oklahoma, 1000 N Lincoln Blvd, #4000, Oklahoma City, OKC, 73104, USA.
Shyian JenDepartment of Neurosurgery, University of Oklahoma, 1000 N Lincoln Blvd, #4000, Oklahoma City, OKC, 73104, USA.
Christopher GraffeoDepartment of Neurosurgery, University of Oklahoma, 1000 N Lincoln Blvd, #4000, Oklahoma City, OKC, 73104, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aneurysmal subarachnoid hemorrhage (aSAH) is a neurosurgical emergency with high morbidity and mortality risks. Vasospasm, a severe subacute complication, may be mitigated by nimodipine, a calcium channel blocker. The optimal duration of nimodipine therapy remains uncertain. We sought to evaluate the optimal duration of nimodipine therapy in relation to overall morbidity in aSAH patients through a systematic review and meta-analysis. A PRISMA-compliant systematic review searched MEDLINE, EMBASE, and Cochrane Library (1/1975-9/2024). Included studies reported nimodipine protocols and standardized outcomes. Data extracted included demographics, nimodipine dosing, duration, and outcomes. The primary outcome was overall morbidity, assessed via extended Glasgow Outcome Scale (eGOS), Glasgow Outcome Scale (GOS), or modified Rankin Scale (mRS). The secondary outcome was neuroimaging-validated delayed cerebral ischemia (DCI) incidence. Random-effects meta-analyses were performed. Fourteen studies (19 cohorts) included 759 standard-of-care (SOC, 21-day nimodipine) and 781 dose duration reduction (DDR, < 21 days) patients. SOC had a pooled favorable outcome proportion of 0.52 [95% CI: 0.34-0.70], versus 0.74 [95% CI: 0.64-0.83] for DDR (p = 0.03). Subgroup analyses showed significant differences by outcome scale (p < 0.01) and administration route (p = 0.01), with oral DDR linked to better outcomes (p = 0.02). Heterogeneity was significant (I

Indexed as

Calcium Channel BlockersNimodipineSubarachnoid HemorrhageVasospasm, IntracranialHumansTreatment OutcomeCalcium Channel BlockersNimodipineAneurysmal subarachnoid hemorrhageMeta-analysisNimodipineSystematic review

Identifiers

PMID40579560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.